Literature DB >> 7601573

Mechanisms of allele-selective down-regulation of HLA class I in Burkitt's lymphoma.

M P Imreh1, Q J Zhang, P O de Campos-Lima, S Imreh, P Krausa, M Browning, G Klein, M G Masucci.   

Abstract

Burkitt lymphomas (BL) that arise in HLA-AII-positive individuals are characterized by selective loss/down-regulation of the HLA AII polypeptide. We have investigated the molecular basis of such down-regulation by comparing 5 pairs of BL lines and Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines (LCL) derived from the normal B cells of the same individuals. The presence of apparently intact HLA AII genes was confirmed in all 5 BL/LCL pairs by polymerase chain reaction (PCR) typing and by Southern-blot hybridization with HLA A locus-specific probes. Northern-blot analysis with locus- and allele-specific probes revealed a significantly lower expression or absence of AII-specific mRNA in all 5 BL lines compared to the corresponding LCLs. Up-regulation of AII-specific mRNA was achieved by IFN alpha treatment of 2 BL lines with low HLA AII expression (BL-28 and BL-72) while the treatment had no effect in 3 BL lines (WWI-BL, WW2-BL and BL41) that did not express the endogenous gene. HLA AII expression was restored by transfection of the gene in WWI-BL whereas transfectants of BL-41 remained AII-negative. An HLA-AII-promoter-driven chloramphenicol acetyl transferase reporter gene (pAIICAT) was active in WWI-BL but not in BL-41. HLA-AII was expressed in hybrids of BL-41 with an AII-positive LCL, while expression of the endogenous HLA AII gene could not be restored by fusion of BL-41 with an AII-negative LCL, although an adequate set of transcription factors was present in the hybrid. Our results suggest that genetic defects and lack of transcription factors may contribute to the selective down-regulation of HLA AII in BL cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7601573     DOI: 10.1002/ijc.2910620117

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  4 in total

1.  MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells.

Authors:  Martin S Staege; Steven P Lee; Teresa Frisan; Josef Mautner; Siegfried Scholz; Alexander Pajic; Alan B Rickinson; Maria G Masucci; Axel Polack; Georg W Bornkamm
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-26       Impact factor: 11.205

2.  Association of HLA alleles with non-Hodgkin's lymphoma in Korean population.

Authors:  Hee-Baeg Choi; Sang-Young Roh; Eun-Jung Choi; Ho-Yeul Yoon; Su-Yeon Kim; Young-Sun Hong; Dong-Wook Kim; Tai-Gyu Kim
Journal:  Int J Hematol       Date:  2008-02-27       Impact factor: 2.490

3.  Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells.

Authors:  Z Wang; F M Marincola; L Rivoltini; G Parmiani; S Ferrone
Journal:  J Exp Med       Date:  1999-07-19       Impact factor: 14.307

Review 4.  Burkitt's lymphoma: the Rosetta Stone deciphering Epstein-Barr virus biology.

Authors:  Martin Rowe; Gemma L Kelly; Andrew I Bell; Alan B Rickinson
Journal:  Semin Cancer Biol       Date:  2009-07-18       Impact factor: 15.707

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.